Table 5. Univariate and multivariate analysis of OS and PFS in AC patients (GUH cohort).
|
Overall survival |
Progression-free survival |
|||||
|---|---|---|---|---|---|---|
| |
Univariate analysis |
Multivariate analysis |
Univariate analysis |
Multivariate analysis |
||
| Variables | 5-Year survival rate (%) | P-value | HR (95% CI) P-value | 5-Year survival rate (%) | P-value | HR (95% CI) P-value |
|
Age | ||||||
| ⩽65 years | 78 | 0.075 | 68 | 0.175 | ||
| >65 years |
67 |
|
|
56 |
|
|
|
Sex | ||||||
| Male | 67 | 0.267 | 0.891 (0.592–1.324) | 58 | 0.509 | 1.056 (0.732–1.506) |
| Female |
74 |
|
0.665 |
63 |
|
0.766 |
|
Smoking | ||||||
| Yes | 63 | 0.046 | 0.898 (0.603–1.354) | 52 | 0.038 | 1.196 (0.823–1.719) |
| No |
77 |
|
0.578 |
68 |
|
0.343 |
|
p-Stage | ||||||
| I or II | 82 | <0.001 | 2.186 (1.614–2.967) | 75 | <0.001 | 2.175 (1.730–2.725) |
| III or IV |
35 |
|
<0.001 |
15 |
|
<0.001 |
|
Lymphatic permeation | ||||||
| Positive | 46 | <0.001 | 32 | <0.001 | ||
| Negative |
86 |
|
|
78 |
|
|
|
Vascular invasion | ||||||
| Positive | 44 | <0.001 | 27 | <0.001 | ||
| Negative |
84 |
|
|
77 |
|
|
|
ASCT2 | ||||||
| High | 59 | 0.009 | 1.424 (1.057–1.929) | 48 | 0.024 | 1.205 (0.919–1.583) |
| Low |
79 |
|
0.012 |
69 |
|
0.177 |
|
CD98 | ||||||
| High | 61 | 0.270 | 37 | 0.021 | ||
| Low |
73 |
|
|
66 |
|
|
|
Ki-67 | ||||||
| High | 51 | 0.001 | 37 | 0.002 | ||
| Low |
78 |
|
|
69 |
|
|
|
CD34 | ||||||
| High | 58 | 0.006 | 43 | 0.013 | ||
| Low |
77 |
|
|
69 |
|
|
|
p-mTOR | ||||||
| High | 64 | 0.243 | 42 | 0.004 | ||
| Low | 75 | 70 | ||||
Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; GUH=Gunma University Hospital; HR=hazard ratio; OS=overall survival; PFS=progression-free survival; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.
Bold entries show statistically significant difference.